Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2024-02-04 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
关于公司药品生产许可证变更的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding a change in their drug production license issued by the Sichuan Provincial Drug Administration. It details the license number, company information, the nature of the change (cancellation of entrusted production), and the impact on the company. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory announcement about a license change, not a financial report or meeting material. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-02-04 Chinese
关于使用自有闲置资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the progress of using its own idle funds to purchase financial products. It includes specifics about the amounts, types of financial products, expected yields, investment directions, and risk control measures. The document is a regulatory disclosure about the company's capital management activities, specifically the use of idle funds for investment in low-risk financial products. It does not contain financial statements, earnings data, or management discussion of financial results. It is not an annual or interim report, nor an earnings release. It is not a call transcript, board change announcement, or legal proceeding. The document is a capital/financing update related to the company's investment of idle funds to improve capital efficiency and generate additional income. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the financing activity, not just a brief announcement or report publication notice.
2024-02-04 Chinese
全资子公司对外投资公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding an external investment by its wholly-owned subsidiary. It details the investment amount, the target company, the strategic rationale, financial data of the target, and the board and supervisory committee approvals. The document explicitly states that the transaction does not constitute a major asset restructuring and is not an affiliated transaction. It includes financial figures but does not present comprehensive financial statements or detailed financial analysis of the company itself. The content focuses on the investment transaction, its purpose, risks, and impact on the company, which aligns with a capital/financing update rather than a full financial report or audit report. There is no indication that this is a full annual or interim report, audit report, or earnings release. The document length (7416 characters) and detailed investment information support classification as a Capital/Financing Update.
2024-01-28 Chinese
第四届监事会第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the second meeting of the fourth Supervisory Board of Sichuan Zitonggong Pharmaceutical Co., Ltd. It details the meeting's time, place, attendance, and the approval of an investment proposal by a wholly-owned subsidiary. The document is an official disclosure of board/committee decisions rather than a full report or financial statement. It does not contain financial data or detailed management analysis, nor is it a regulatory filing or announcement of voting results. The content aligns with Board/Management Information (MANG) as it relates to internal governance decisions and supervisory board resolutions.
2024-01-28 Chinese
第四届董事会第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the company's board of directors meeting, including details about meeting attendance, agenda items, and voting results. It does not contain financial statements or detailed financial analysis. The content focuses on board decisions regarding investments and license changes, typical of board meeting resolutions. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report or presentation but a meeting resolution announcement.
2024-01-28 Chinese
关于使用自有闲置资金购买理财产品的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the progress of using its own idle funds to purchase financial products. It includes specifics about the amounts, types, expected yields, investment periods, and risk controls related to these financial products. The document references board and shareholder meetings approving the use of funds for purchasing low-risk short-term financial products. It is a regulatory disclosure about capital management and investment activities, focusing on financing and capital usage updates rather than financial results, management changes, or legal matters. The document length is 7,526 characters, which is substantial and contains detailed financial investment information, not just a brief announcement or a certification. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2024-01-23 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.